David Macdonald - The Ottawa Hospital, University of Ottawa

基本信息

浏览量：64

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 122 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Maintenance Therapy for CD20+ Indolent Lymphoma: Who Should Receive Maintenance

Edward Koo,David A. Macdonald

Canadian Hematology Today (2024)

引用0浏览0引用

Brentuximab Vedotin (BV) in Combination with Lenalidomide (len) and Rituximab (R) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results from the Phase 3 ECHELON-3 Study

Jeong A. Kim,Uwe Hahn,Won-Seog Kim,Isabelle Fleury,Kamel Laribi,Juan Miguel Bergua Burgues,Krimo Bouabdallah,Nick Forward,Fontanet Bijou,David MacDonald, Craig Anthony Portell,Herve Ghesquieres,Grzegorz S. Nowakowski,Christopher A. Yasenchak, Evelyn Rustia,Michelle Fanale, Fei Jie,Nancy L. Bartlett

Journal of Clinical Oncologyno. 17_suppl (2024): LBA7005-LBA7005

引用0浏览0引用

ABCL-711 Brentuximab Vedotin (BV) in Combination with Lenalidomide (len) and Rituximab (R) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results from the Phase 3 ECHELON-3 Study

Christopher Yasenchak, Jeong-AA Kim, Uwe Hahn, Seog,Isabelle Fleury,Kamel Laribi,Juan Miguel Bergua Burgues, Krimo Bouabdallah,Nicholas Forward,Fontanet Bijou,David MacDonald,Craig Portell,Herve Ghesquieres, Grzegorz Nowakowski, Evelyn Rustia,Michelle Fanale, Fei Jie,Nancy Bartlett

Clinical Lymphoma Myeloma and Leukemia (2024)

引用0浏览0引用

Indolent Lymphoma: Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM)

Neil L. Berinstein, Kristian Roos,Gail Klein,Rebecca F. McClure,Nicholas Forward,Mona Shafey,Alexandra Nikonova,David MacDonald,Diego Villa,Irwindeep Sandhu,Mohammed A. Aljama,Jean-François Larouche,KATHRYN MANGOFF

Hematological oncologyno. S2 (2023): 396-397

引用0浏览0引用

Falls and Falls-Related Injuries in Individuals with Chronic Ankle Symptoms: a Cross-Sectional Study

Munira M. Al Mahrouqi,Bill Vicenzino,David A. MacDonald,Michelle D. Smith

Journal of Foot and Ankle Research（2023）

引用0浏览0WOS引用

Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)

Neil Berinstein,Kim Roos,Kathryn Mangoff,Yidi Jiang,Gail Klein,Rebecca McClure,Nicholas Forward,Mona Shafey,Anna Nikonova,David MacDonald,Diego Villa,Irwindeep Sandhu,Mohammed Aljama,Jean-Francois Larouche, Monica Gallucci,Heidi Simmons

Bloodno. Supplement 1 (2023): 3037-3037

引用0浏览0引用

Supplementary Tables 1 and 2 from Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma

Michinori Ogura,Kensei Tobinai,Kiyohiko Hatake, Andrew Davies,Michael Crump,Revathi Ananthakrishnan,Taro Ishibashi,M. Luisa Paccagnella,Joseph Boni,Erik Vandendries,David MacDonald

crossref（2023）

引用0浏览0引用

Cranial Radiation Therapy as Salvage in the Treatment of Relapsed Primary CNS Lymphoma

Matthew E. Volpini,Jiheon Song,Rajiv Samant,David MacDonald,Vimoj J. Nair

CURRENT ONCOLOGYno. 11 (2022): 8160-8170

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn